AIM ImmunoTech Inc. [AMEX: AIM] loss 0.00% on the last trading session, reaching $3.07 price per share at the time. The company report on July 9, 2020 that AIM ImmunoTech Signs Clinical Trial Agreement with Roswell Park Comprehensive Cancer Center Supporting Phase 1/2 Clinical Trial of Ampligen Combined with Interferon Alfa-2b in COVID-19 Patients with Cancer.
AIM ImmunoTech (NYSE AMERICAN:AIM), today announced that it has entered into a clinical trial agreement (CTA) with Roswell Park Comprehensive Cancer Center to support Roswell Park’s Phase 1/2a trial of Ampligen (rintatolimod) in combination with interferon alfa-2b, in cancer patients with COVID-19, the disease caused by the SARS-CoV-2 coronavirus. Funding for the clinical trial is provided, in part, through grants from the National Cancer Institute and AIM, as well as institutional support from Roswell Park.
Thomas K. Equels, CEO of AIM ImmunoTech, commented, “We are excited to team up with Roswell Park, a leading cancer research center, to test Ampligen as part of an antiviral treatment combination for COVID-19 among cancer patients. Based on the preclinical studies, we are encouraged by the potential for an effective early-onset treatment against this new and deadly virus especially for cancer patients, who face significantly increased risk of severe symptoms or death. We look forward to leveraging this important clinical trial for cancer patients with COVID-19, if successful, into tests of Ampligen in other high risk and immunocompromised COVID-19 groups.”.
AIM ImmunoTech Inc. represents 32.62 million in outstanding shares, while the company has a total market value of $100.20 million with the latest information. AIM stock price has been found in the range of $2.81 to $3.16.
If compared to the average trading volume of 5.69M shares, AIM reached a trading volume of 4400276 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Here is what top equities market gurus are saying about AIM ImmunoTech Inc. [AIM]:
The Average True Range (ATR) for AIM ImmunoTech Inc. is set at 0.34, with the Price to Sales ratio for AIM stock in the period of the last 12 months amounting to 501.02. The Price to Book ratio for the last quarter was 1.57, with the Price to Cash per share for the same quarter was set at 0.86.
Trading performance analysis for AIM stock
AIM ImmunoTech Inc. [AIM] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 0.99. With this latest performance, AIM shares gained by 35.24% in over the last four-week period, additionally plugging by 169.30% over the last 6 months – not to mention a rise of 11.23% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for AIM stock in for the last two-week period is set at 55.97, with the RSI for the last a single of trading hit 53.82, and the three-weeks RSI is set at 55.62 for AIM ImmunoTech Inc. [AIM]. The present Moving Average for the last 50 days of trading for this stock 2.65, while it was recorded at 3.35 for the last single week of trading, and 1.64 for the last 200 days.
AIM ImmunoTech Inc. [AIM]: A deeper dive into fundamental analysis
Operating Margin for any stock indicates how profitable investing would be, and AIM ImmunoTech Inc. [AIM] shares currently have an operating margin of -8831.43 and a Gross Margin at -537.86. AIM ImmunoTech Inc.’s Net Margin is presently recorded at -6809.29.
Return on Total Capital for AIM is now -81.38, given the latest momentum, and Return on Invested Capital for the company is -71.87. Return on Equity for this stock declined to -105.45, with Return on Assets sitting at -16.18. When it comes to the capital structure of this company, AIM ImmunoTech Inc. [AIM] has a Total Debt to Total Equity ratio set at 49.43. Additionally, AIM Total Debt to Total Capital is recorded at 33.08, with Total Debt to Total Assets ending up at 10.02. Long-Term Debt to Equity for the company is recorded at 50.52, with the Long-Term Debt to Total Capital now at 31.77.
Reflecting on the efficiency of the workforce at the company, AIM ImmunoTech Inc. [AIM] managed to generate an average of -$366,654 per employee. Receivables Turnover for the company is 0.15 with a Total Asset Turnover recorded at a value of 0.00.AIM ImmunoTech Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 42.30 and a Current Ratio set at 42.30.
AIM ImmunoTech Inc. [AIM]: An earnings per share (EPS) analysis
With the latest financial reports released by the company, AIM ImmunoTech Inc. posted -1.07/share EPS, while the average EPS was predicted by analysts to be reported at -1.7/share. When compared, the two values demonstrate that the company surpassed the estimates by a Surprise Factor of 37.10%. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for AIM. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for AIM ImmunoTech Inc. go to 25.00%.
An analysis of insider ownership at AIM ImmunoTech Inc. [AIM]
There are presently around $2 million, or 1.80% of AIM stock, in the hands of institutional investors. The top three institutional holders of AIM stocks are: MILLENNIUM MANAGEMENT LLC with ownership of 194,404, which is approximately New of the company’s market cap and around 2.00% of the total institutional ownership; HUDSON BAY CAPITAL MANAGEMENT LP, holding 127,770 shares of the stock with an approximate value of $0.39 million in AIM stocks shares; and VANGUARD GROUP INC, currently with $0.27 million in AIM stock with ownership of nearly New of the company’s market capitalization.
Positions in AIM ImmunoTech Inc. stocks held by institutional investors increased at the end of May and at the time of the May reporting period, where 19 institutional holders increased their position in AIM ImmunoTech Inc. [AMEX:AIM] by around 565,338 shares. Additionally, 6 investors decreased positions by around 550,486 shares, while 7 investors held positions by with 536,500 shares. The mentioned changes placed institutional holdings at 579,324 shares, according to the latest SEC report filing. AIM stock had 16 new institutional investments in for a total of 507,369 shares, while 5 institutional investors sold positions of 550,478 shares during the same period.